David Henry Mack - 18 Jan 2024 Form 4 Insider Report for PMV Pharmaceuticals, Inc. (PMVP)

Role
President and CEO, Director
Signature
/s/ David H. Mack
Issuer symbol
PMVP
Transactions as of
18 Jan 2024
Net transactions value
$0
Form type
4
Filing time
22 Jan 2024, 16:02:42 UTC
Previous filing
13 Nov 2023
Next filing
03 Oct 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PMVP Common Stock Award $0 +163,890 +59% $0.000000 442,460 18 Jan 2024 Direct F1
holding PMVP Common Stock 165,307 18 Jan 2024 See footnote F2
holding PMVP Common Stock 147,915 18 Jan 2024 See footnote F2, F3
holding PMVP Common Stock 56,978 18 Jan 2024 See footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PMVP Employee Stock Option (right to buy) Award $0 +519,915 $0.000000 519,915 18 Jan 2024 Common Stock 519,915 $1.80 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported shares are represented by restricted stock units, or RSUs, all of which vest on June 30, 2025.
F2 The shares are held of record by the Stinson 2021 Irrevocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.
F3 The shares are held of record by The Mack-Mulligan Revocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.
F4 Shares subject to the option vest in 48 equal monthly installments beginning on February 18, 2024.

Remarks:

Exhibit 24 - Power of Attorney